US5780587A
(en)
*
|
1990-08-24 |
1998-07-14 |
President And Fellows Of Harvard College |
Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
|
AU652997B2
(en)
*
|
1991-01-21 |
1994-09-15 |
Elan Pharmaceuticals, Inc. |
Test and model for alzheimer's disease
|
JPH07506720A
(en)
*
|
1992-01-07 |
1995-07-27 |
アテナ ニューロサイエンシーズ, インコーポレイテッド |
Transgenic animal model of Alzheimer's disease
|
US6610493B1
(en)
*
|
1993-06-17 |
2003-08-26 |
Brigham And Women's Hospital |
Screening compounds for the ability to alter the production of amyloid-β peptide
|
JPH09507746A
(en)
*
|
1993-10-27 |
1997-08-12 |
アテナ ニューロサイエンシズ,インコーポレイティド |
Transgenic animal containing APP allele with Swedish mutation
|
WO1995020666A2
(en)
|
1994-01-27 |
1995-08-03 |
Regents Of The University Of Minnesota |
Transgenic non-human mammals with progressive neurologic disease
|
US5877399A
(en)
*
|
1994-01-27 |
1999-03-02 |
Johns Hopkins University |
Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
|
US7427392B1
(en)
*
|
1994-11-14 |
2008-09-23 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
|
US5804560A
(en)
*
|
1995-01-06 |
1998-09-08 |
Sibia Neurosciences, Inc. |
Peptide and peptide analog protease inhibitors
|
US6017887A
(en)
*
|
1995-01-06 |
2000-01-25 |
Sibia Neurosciences, Inc. |
Peptide, peptide analog and amino acid analog protease inhibitors
|
CA2221986A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Athena Neurosciences, Inc. |
Method for identifying alzheimer's disease therapeutics using transgenic animal models
|
US6717031B2
(en)
*
|
1995-06-07 |
2004-04-06 |
Kate Dora Games |
Method for selecting a transgenic mouse model of alzheimer's disease
|
US5894078A
(en)
*
|
1996-02-26 |
1999-04-13 |
Advanced Bioconcept, Inc. |
Transgenic mouse expressing C-100 app
|
US6043283A
(en)
*
|
1996-09-20 |
2000-03-28 |
Baylor College Of Medicine |
Tyramine compounds and their neuronal effects
|
US6071493A
(en)
|
1996-09-20 |
2000-06-06 |
Baylor College Of Medicine |
Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
|
US5898094A
(en)
*
|
1996-10-21 |
1999-04-27 |
University Of South Florida |
Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
|
US8173127B2
(en)
*
|
1997-04-09 |
2012-05-08 |
Intellect Neurosciences, Inc. |
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
|
US6455757B1
(en)
|
1997-10-08 |
2002-09-24 |
The Regents Of The University Of California |
Transgenic mice expressing human APP and TGF-β demonstrate cerebrovascular amyloid deposits
|
US6175057B1
(en)
|
1997-10-08 |
2001-01-16 |
The Regents Of The University Of California |
Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US6743427B1
(en)
|
1997-12-02 |
2004-06-01 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7790856B2
(en)
*
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
AU781126B2
(en)
*
|
1997-12-03 |
2005-05-05 |
Janssen Alzheimer Immunotherapy |
Method of suppressing beta-amyloid-related changes in Alzheimer's disease
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
CA2328591A1
(en)
*
|
1998-05-15 |
1999-11-25 |
Ortho-Mcneil Pharmaceutical, Inc. |
Irak modified transgenic animals
|
US20030147882A1
(en)
*
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
US6245884B1
(en)
|
1998-10-16 |
2001-06-12 |
Vivian Y. H. Hook |
Secretases related to alzheimer's dementia
|
US6313268B1
(en)
|
1998-10-16 |
2001-11-06 |
Vivian Y. H. Hook |
Secretases related to Alzheimer's dementia
|
US6737038B1
(en)
*
|
1998-11-12 |
2004-05-18 |
Bristol-Myers Squibb Company |
Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
|
CA2358086A1
(en)
*
|
1998-12-22 |
2000-06-29 |
Myriad Genetics, Inc. |
Protein-protein interactions in neurodegenerative disorders
|
US7115410B1
(en)
*
|
1999-02-10 |
2006-10-03 |
Elan Pharmaceuticals, Inc. |
β-secretase enzyme compositions and methods
|
WO2000059297A2
(en)
|
1999-04-06 |
2000-10-12 |
Harrington Arthritis Research Center |
Methods for tracking the progression of alzheimer's disease and identifying treatments using transgenic mice
|
US20030131364A1
(en)
*
|
1999-04-27 |
2003-07-10 |
Karen Duff |
Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
|
US6670195B1
(en)
|
1999-05-26 |
2003-12-30 |
New York University |
Mutant genes in Familial British Dementia and Familial Danish Dementia
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
UA81216C2
(en)
*
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
ATE343562T1
(en)
*
|
2000-03-23 |
2006-11-15 |
Elan Pharm Inc |
COMPOUNDS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
US7358090B2
(en)
*
|
2000-03-24 |
2008-04-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
Establishment of cellular manipulations which enhance oligo-mediated gene targeting
|
US7371920B2
(en)
*
|
2000-06-20 |
2008-05-13 |
The Governing Council Of The University Of Toronto |
Transgenic mouse model of neurodegenerative disorders
|
AU2001271686A1
(en)
|
2000-06-30 |
2002-01-14 |
Elan Pharmaceuticals, Inc. |
Compounds to treat alzheimer's disease
|
US6846813B2
(en)
*
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
US6686449B2
(en)
|
2000-06-30 |
2004-02-03 |
Pharmacia & Upjohn Company |
Mutant presenilin 1 polypeptides
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
EP1666452A2
(en)
|
2000-06-30 |
2006-06-07 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
PE20020276A1
(en)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER
|
AU2007200047B2
(en)
*
|
2000-07-07 |
2009-11-26 |
Bioarctic Neuroscience Ab |
Prevention and treatment of Alzheimer's disease
|
WO2002003911A2
(en)
*
|
2000-07-07 |
2002-01-17 |
Lars Lannfelt |
Prevention and treatment of alzheimer's disease
|
PE20020574A1
(en)
*
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
EP1434988A4
(en)
*
|
2001-02-23 |
2005-12-14 |
Elan Pharm Inc |
Transgenic knockouts of bace-1
|
US6649196B2
(en)
*
|
2001-03-12 |
2003-11-18 |
Mayo Foundation For Medical Education And Research |
Methods of reducing β-amyloid polypeptides
|
US7081561B2
(en)
|
2001-03-16 |
2006-07-25 |
The Regents Of The University Of California |
Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
|
AU2002257162A1
(en)
*
|
2001-04-30 |
2002-11-11 |
Eli Lilly And Company |
Humanized antibodies
|
BR0210122A
(en)
*
|
2001-06-01 |
2004-06-15 |
Elan Pharm Inc |
Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same
|
JP2004532894A
(en)
|
2001-06-13 |
2004-10-28 |
イーラン ファーマスーティカルズ、インコーポレイテッド |
Amine diol for treating Alzheimer's disease
|
AU2002318364A1
(en)
|
2001-06-14 |
2003-01-02 |
Bristol-Myers Squibb Company |
Novel human histone deacetylases
|
JP2005500319A
(en)
*
|
2001-06-27 |
2005-01-06 |
イーラン ファーマスーティカルズ、インコーポレイテッド |
Β-hydroxyamine derivatives useful for the treatment of Alzheimer's disease
|
US7829087B2
(en)
*
|
2001-07-09 |
2010-11-09 |
Elan Pharmaceuticals, Inc. |
Methods of treating cognitive impairment
|
EP1414491A4
(en)
*
|
2001-07-09 |
2005-07-06 |
Elan Pharm Inc |
Methods of inhibiting amyloid toxicity
|
EP1406617A1
(en)
*
|
2001-07-10 |
2004-04-14 |
Elan Pharmaceuticals, Inc. |
Diaminediols for the treatment of alzheimer's disease
|
WO2003006453A1
(en)
*
|
2001-07-10 |
2003-01-23 |
Elan Pharmaceuticals, Inc. |
Aminediols for the treatment of alzheimer's disease
|
US7297553B2
(en)
*
|
2002-05-28 |
2007-11-20 |
Nanosphere, Inc. |
Method for attachment of silylated molecules to glass surfaces
|
BR0213139A
(en)
*
|
2001-10-04 |
2004-08-10 |
Elan Pharm Inc |
Compound, method of treating or preventing disease and preparing a compound, use of a compound and pharmaceutical composition
|
US7176242B2
(en)
*
|
2001-11-08 |
2007-02-13 |
Elan Pharmaceuticals, Inc. |
N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives
|
BR0214297A
(en)
*
|
2001-11-19 |
2004-11-09 |
Upjohn Co |
Methods of treating or preventing alzheimer's disease in an individual is a disease distinguished by beta-amyloid deposits on or in the brain, treating alzheimer's disease in an individual who has, or preventing an individual from acquiring a disease or condition from inhibit beta-secretase activity, cleavage of an amyloid precursor protein isotype and production of beta-amyloid peptide and beta-amyloid plaque in an animal and to produce a beta-secretase complex and use of a compound, and, composition
|
MY139983A
(en)
*
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US7262208B2
(en)
*
|
2002-04-30 |
2007-08-28 |
Elan Pharmaceuticals, Inc. |
Hydroxypropyl amides for the treatment of Alzheimer's disease
|
US20040009602A1
(en)
*
|
2002-05-13 |
2004-01-15 |
The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services |
DNA modifying molecules and methods of use thereof
|
UY27967A1
(en)
*
|
2002-09-10 |
2004-05-31 |
Pfizer |
2-HINDROXI-1,3-DIAMINOALCANE OIL
|
US9535076B2
(en)
|
2002-09-12 |
2017-01-03 |
The Regents Of The University Of California |
Methods and compositions for eliciting an amyloid-selective immune response
|
MXPA05003621A
(en)
*
|
2002-10-09 |
2005-10-19 |
Rinat Neuroscience Corp |
Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof.
|
US20080014194A1
(en)
*
|
2003-10-31 |
2008-01-17 |
Elan Pharmaceuticals, Inc. |
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
|
US9034337B2
(en)
|
2003-10-31 |
2015-05-19 |
Prothena Biosciences Limited |
Treatment and delay of outset of synucleinopathic and amyloidogenic disease
|
US8506959B2
(en)
*
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
US20070099185A1
(en)
*
|
2002-11-04 |
2007-05-03 |
Bioarctic Neuroscience Ab |
Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
|
JP2006505271A
(en)
*
|
2002-11-04 |
2006-02-16 |
アイコジェネックス コーポレイション |
Methods for the identification of substances that modulate the structure and processing of membrane-bound precursor proteins
|
BR0316629A
(en)
*
|
2002-11-27 |
2005-10-11 |
Elan Pharm Inc |
Substituted urea and carbamates
|
US20070010435A1
(en)
|
2002-12-19 |
2007-01-11 |
New York University |
Method for treating amyloid disease
|
DE10303974A1
(en)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid β (1-42) oligomers, process for their preparation and their use
|
WO2004069182A2
(en)
*
|
2003-02-01 |
2004-08-19 |
Neuralab Limited |
Active immunization to generate antibodies to soluble a-beta
|
UY28280A1
(en)
|
2003-04-21 |
2004-11-30 |
Pharmacia & Amp |
2- HYDROXI - 3- DIAMINOALCANOS DE BENZAMIDA
|
WO2004094413A1
(en)
*
|
2003-04-21 |
2004-11-04 |
Elan Pharmaceuticals, Inc. |
Phenacyl 2-hydroxy-3-diaminoalkanes
|
CN102584813B
(en)
*
|
2003-05-14 |
2016-07-06 |
Ngc药物公司 |
Compound and the purposes in regulating amyloid beta thereof
|
PL2361928T3
(en)
*
|
2003-05-19 |
2017-09-29 |
Prothena Biosciences Limited |
Truncated fragments of alpha-synuclein in Lewy body disease
|
US7358331B2
(en)
*
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
TWI374893B
(en)
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
AT413336B
(en)
*
|
2003-09-12 |
2006-02-15 |
Mattner Frank Dr |
APHERESIS DEVICE
|
US7674599B2
(en)
|
2003-11-08 |
2010-03-09 |
Elan Pharmaceuticals, Inc. |
Methods of using antibodies to detect alpha-synuclein in fluid samples
|
US20060014790A1
(en)
*
|
2004-01-21 |
2006-01-19 |
Varghese John |
Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
|
JP2007528400A
(en)
*
|
2004-03-09 |
2007-10-11 |
エラン ファーマシューティカルズ,インコーポレイテッド |
Substituted hydroxyethylamine aspartic protease inhibitors
|
EP1734942A1
(en)
*
|
2004-03-09 |
2006-12-27 |
Elan Pharmaceuticals, Inc. |
Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
|
JP2007528403A
(en)
*
|
2004-03-09 |
2007-10-11 |
エラン ファーマシューティカルズ,インコーポレイテッド |
Methods for treating amyloidosis using bicyclic aspartic protease inhibitors
|
EP1735293A2
(en)
*
|
2004-03-09 |
2006-12-27 |
Elan Pharmaceuticals, Inc. |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
US20060014737A1
(en)
*
|
2004-03-09 |
2006-01-19 |
Varghese John |
Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
|
SE0400707D0
(en)
|
2004-03-22 |
2004-03-22 |
Bioarctic Neuroscience Ab |
Transgenic animal model
|
WO2005110422A2
(en)
*
|
2004-05-19 |
2005-11-24 |
Boehringer Ingelheim International Gmbh |
Treatment of diseases associated with altered level of amyloid beta peptides
|
WO2005116657A2
(en)
|
2004-05-24 |
2005-12-08 |
Universität Zu Köln |
Identification of ergothioneine transporter and therapeutic uses thereof
|
SE0401601D0
(en)
|
2004-06-21 |
2004-06-21 |
Bioarctic Neuroscience Ab |
Protofibril specific antibodies and uses thereof
|
US7385085B2
(en)
*
|
2004-07-09 |
2008-06-10 |
Elan Pharmaceuticals, Inc. |
Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
|
CA2572775A1
(en)
|
2004-07-09 |
2006-01-26 |
Elan Pharmaceuticals, Inc. |
Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
|
NZ552480A
(en)
*
|
2004-07-30 |
2010-01-29 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods of using same
|
US8436006B2
(en)
*
|
2004-08-06 |
2013-05-07 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
US8383637B2
(en)
*
|
2004-08-06 |
2013-02-26 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
US8426429B2
(en)
*
|
2004-08-06 |
2013-04-23 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
MX2007001679A
(en)
|
2004-08-09 |
2007-05-23 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic and amyloidogenic disease.
|
WO2006026533A2
(en)
*
|
2004-08-27 |
2006-03-09 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
|
TW200635608A
(en)
*
|
2004-12-15 |
2006-10-16 |
Neuralab Ltd |
Aβ antibodies for use in improving cognition
|
JP2008523815A
(en)
*
|
2004-12-15 |
2008-07-10 |
エラン ファーマ インターナショナル リミテッド |
Humanized amyloid beta antibody for use in improving cognition
|
AR051528A1
(en)
*
|
2004-12-15 |
2007-01-17 |
Neuralab Ltd |
HUMANIZED ANTIBODIES RECOGNIZING THE BETA AMILOIDEO PEPTIDE
|
WO2006089095A2
(en)
|
2005-02-17 |
2006-08-24 |
Biogen Idec Ma Inc. |
Treating neurological disorders
|
MY148086A
(en)
*
|
2005-04-29 |
2013-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
EP1746092A1
(en)
|
2005-07-22 |
2007-01-24 |
Exonhit Therapeutics SA |
Compounds and methods for treatment of amyloid-B-peptide related disorders
|
WO2007014946A1
(en)
*
|
2005-08-03 |
2007-02-08 |
Boehringer Ingelheim International Gmbh |
Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
|
WO2007017510A2
(en)
*
|
2005-08-11 |
2007-02-15 |
Boehringer Ingelheim International Gmbh |
Isophthalic acid diamides for treating alzheimer's disease
|
JP2009504614A
(en)
*
|
2005-08-11 |
2009-02-05 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Compounds for the treatment of Alzheimer's disease
|
EP1915339A1
(en)
*
|
2005-08-11 |
2008-04-30 |
Boehringer Ingelheim International GmbH |
Beta-secretase inhibitors for use in the treatment of alzheimer's disease
|
US20090042867A1
(en)
*
|
2005-08-11 |
2009-02-12 |
Klaus Fuchs |
Compounds for the treatment of alzheimer's disease
|
WO2007047305A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
|
WO2007047306A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
|
KR101667623B1
(en)
|
2005-11-30 |
2016-10-19 |
애브비 인코포레이티드 |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
BRPI0619249A2
(en)
|
2005-11-30 |
2011-09-20 |
Abbott Lab |
anti-globulin-ß antibodies, antigen-binding fractions thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of making said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
|
ES2316209B1
(en)
*
|
2005-12-02 |
2009-11-13 |
Universidad Autonoma De Madrid |
ANZAL MODEL OF ALZHEIMER'S DISEASE, PROCEDURE OF OBTAINING AND ITS APPLICATIONS.
|
US7932261B2
(en)
*
|
2006-02-06 |
2011-04-26 |
Janssen Pharmaceutica Nv |
Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
|
US7868022B2
(en)
*
|
2006-02-06 |
2011-01-11 |
Janssen Pharmaceutica Nv |
2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
|
US7776882B2
(en)
*
|
2006-02-06 |
2010-08-17 |
Baxter Ellen W |
2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
|
NZ567888A
(en)
|
2006-03-23 |
2010-08-27 |
Bioarctic Neuroscience Ab |
Improved protofibril selective antibodies and the use thereof
|
US8784810B2
(en)
*
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
US20070292895A1
(en)
*
|
2006-05-19 |
2007-12-20 |
Xiao-Ping Shi |
Assays and methods to detect beta-secretase and its activity in body fluids and tissue extracts
|
EP2035448A4
(en)
|
2006-06-01 |
2010-11-03 |
Elan Pharm Inc |
Neuroactive fragments of app
|
CA2657681C
(en)
|
2006-07-14 |
2019-03-19 |
Ac Immune S.A. |
Humanized antibodies against beta amyloid protein
|
CN101600730B
(en)
|
2006-10-12 |
2014-01-29 |
Bhi有限合资公司 |
Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
US8147833B2
(en)
*
|
2007-02-23 |
2012-04-03 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
LT3067066T
(en)
|
2007-02-23 |
2019-06-25 |
Prothena Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
DK3067066T3
(en)
*
|
2007-02-23 |
2019-05-20 |
Prothena Biosciences Ltd |
PREVENTION AND TREATMENT OF SYNUCLEINOPATIC AND AMYLOIDOGENIC DISEASE
|
EP2124952A2
(en)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
US20110286997A1
(en)
|
2007-03-13 |
2011-11-24 |
Hakon Hakonarson |
Genetic Alterations on Chromosome 16 and Methods of Use Thereof for the Diagnosis and Treatment of Type 1 Diabetes
|
BRPI0810118A8
(en)
*
|
2007-04-18 |
2015-09-29 |
Janssen Alzheimer Immunotherap |
METHOD TO TREAT DISEASE, METHOD TO EFFECT CAA PROPHYLAXIS, USE OF AN AGENT, METHOD TO REDUCE VASCULAR AMYLOID IN A PATIENT, AND, KIT FOR TREATMENT
|
US8003097B2
(en)
*
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
CA2687750C
(en)
|
2007-07-06 |
2016-10-18 |
Boehringer Ingelheim International Gmbh |
Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
|
JP2010533478A
(en)
|
2007-07-13 |
2010-10-28 |
エラン ファーマシューティカルズ,インコーポレイテッド |
Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
|
DK2182983T3
(en)
|
2007-07-27 |
2014-07-14 |
Janssen Alzheimer Immunotherap |
TREATMENT OF AMYLOIDOGENIC DISEASES WITH HUMANIZED ANTI-ABETA ANTIBODIES
|
PL2238166T3
(en)
|
2007-10-05 |
2014-07-31 |
Genentech Inc |
Use of anti-amyloid beta antibody in ocular diseases
|
JO3076B1
(en)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
Immunotherapy regimes dependent on apoe status
|
US20090163594A1
(en)
*
|
2007-10-31 |
2009-06-25 |
Elan Pharmaceuticals, Inc. |
Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
|
CN101925578B
(en)
*
|
2008-01-28 |
2012-11-28 |
詹森药业有限公司 |
6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of ss-secretase (BACE)
|
JP2011510993A
(en)
*
|
2008-01-29 |
2011-04-07 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
2-Amino-quinoline derivatives useful as β-secretase (BACE) inhibitors
|
DK2257643T3
(en)
|
2008-02-19 |
2015-06-29 |
Philadelphia Children Hospital |
Identification of pediatric onset of inflammatory bowel disease-loco and methods of use thereof for diagnosis and treatment thereof
|
EP2291544B1
(en)
|
2008-05-16 |
2017-10-25 |
The Children's Hospital of Philadelphia |
Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
US20110023152A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of cognition related genes in animals
|
LT2448968T
(en)
|
2009-06-29 |
2021-05-10 |
Bioarctic Ab |
ANTIBODIES SELECTIVE FOR N-TERMINALTRUNCATED AMYLOID-p PROTOFIBRILS/OLIGOMERS
|
CN102933601B
(en)
|
2010-04-15 |
2016-06-08 |
Abbvie公司 |
Amyloid beta is in conjunction with albumen
|
RU2607368C2
(en)
|
2010-07-30 |
2017-01-10 |
Ац Иммуне С.А. |
Safe and functional humanized antibodies
|
US9062101B2
(en)
|
2010-08-14 |
2015-06-23 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
US10449177B2
(en)
|
2010-08-19 |
2019-10-22 |
Buck Institute For Research On Aging |
Methods of treating mild cognitive impairment (MCI) and related disorders
|
EP3607946B1
(en)
|
2012-03-19 |
2023-02-22 |
Buck Institute for Research on Aging |
App specific bace inhibitors (asbis) and uses thereof
|
WO2014127042A1
(en)
|
2013-02-12 |
2014-08-21 |
Buck Institute For Research On Aging |
Hydantoins that modulate bace-mediated app processing
|
JO3537B1
(en)
|
2014-07-10 |
2020-07-05 |
Bioarctic Neuroscience Ab |
Improved AB protofibril binding antibodies
|
EP3212811B1
(en)
|
2014-10-29 |
2020-09-09 |
The Children's Hospital of Philadelphia |
Diagnosis of genetic alterations associated with eosinophilic esophagitis
|
AU2016313506A1
(en)
|
2015-08-21 |
2018-03-08 |
The Children's Hospital Of Philadelphia |
Methods of treating autoimmune conditions in patients with genetic variations in DcR3 or in a DcR3 network gene
|
EP3341362B1
(en)
|
2015-08-27 |
2023-07-05 |
Nantneuro, LLC |
Compositions for app-selective bace inhibition and uses therfor
|
WO2017197177A1
(en)
|
2016-05-12 |
2017-11-16 |
Buck Institute For Research On Aging |
Compounds to promote normal processing of app
|